SCRS Welcomes StudyKIK
The Society for Clinical Research Sites (SCRS) announced that StudyKIK has joined the organization as a Global Impact Partner (GIP). SCRS’ GIP Program provides an opportunity for sponsors, CROs, and solution providers to engage with SCRS and its members. Becoming a GIP demonstrates StudyKIK’s commitment to clinical research sites, their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions in the marketplace.
"StudyKIK has believed in SCRS and the vision Christine Pierre founded the organization on, which is to be the unified voice for all research sites, since its inception," said the company's president and co-founder, Matt Miller. "We started StudyKIK with the same vision by building tools to empower sites to succeed in patient recruitment. Becoming an SCRS Global Impact Partner strengthens our commitment to supporting research sites and connecting patients to clinical trials."
“By joining SCRS as a GIP, StudyKIK has demonstrated their commitment to a strong and unified site community,” said SCRS president Casey Orvin. “StudyKIK has had a consistent presence at SCRS’ Site Solutions Summits throughout the years, and we are looking forward to expanding our engagement with the company through the GIP program.”
For more information, visit www.MySCRS.org
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
